, there are specific cellular and humoral immune responses to tumour-associated antigens. A significant increase in Epstein-Barr (EB) virus antibodies has been observed using immunofluorescence methods in Hodgkin"s patients, particularly those with mixed cellularity and lymphocyte depletion (Johansson et al. 1970 , Levine et al. 1971 , indicating the presence of EB-associated intracellular and cell membrane antigens. These studies add to the already established disease-associated EBvirus antibody patterns in Burkitt's lymphoma and nasopharyngeal carcinoma (Klein 1971 ) and draw attention to the possible relation between infectious mononucleosis and Hodgkin's disease (Kaplan 1971) . Immunofluorescence studies with heterologous antisera against perisplenic lymph nodes and splenic tumour nodules from Hodgkin's patients have also detected cross-reacting abnormal antigens not present in normal splenic tissue, but as yet the specificity of these antigens remains unexplored (Order et al. 1971 ).
Impairment of cell-mediated immunity in
Hodgkin's patients has been frequently demonstrated by showing depressed hypersensitivity responses to agents such as dinitrochlorobenzene (DNCB) and bacterial antigens (Brown et al. 1967 , Kaplan 1970 ). These observations have been interpreted as showing that Hodgkin's disease is characterized by a progressive loss of thymus-derived (T cell) lymphocytes which are functionally involved in immunosurveillance mechanisms (Good et al. 1971) . More definitive studies of the cellular immune defect in early untreated patients are needed to reconcile the contradictory findings of Brown et al. (1967) and Kaplan (1970) , but recent unpublished studies by Kaplan (1971) confirm that defective responses to DNCB hypersensitization occur at early stages.
These findings focus attention on the mechanism of the aberration and its progressive increase with advanced disease. The possibility must also be considered that humoral and cell-mediated factors act antagonistically, since there is evidence to support this concept from studies of a variety of both experimental and human solid tumours (Baldwin 1971 , Hellstrom & Hellstrom 1970 , Hellstrom et al. 1971 ). Thirty years ago Hodgkin's disease and allied lymph node disorders were accepted as inevitably fatal. Investigations were limited usually to a simple chest X-ray and blood count and early treatment was either avoided, until troublesome symptoms developed, or limited to the irradiation of small localized groups of superficial lymph nodes. This approach was justifiable if one accepted that these disorders were inevitably fatal. Clearly no doctor would wish to submit his patient to unnecessary and possibly unpleasant investigations when no cure was possible. Modern concepts have completely altered this pessimistic approach. The previous speakers have indicated that radical investigation and energetic treatment must now be accepted in the management and cure of 'incurable' Hodgkin's disease. Neither radical investigation nor energetic treatment are complication-free, and it is necessary to examine these new vigorous approaches to make sure that they are justifiable. Is Hodgkin's Disease Curable? Dr W B Dawson (see above, p 1109) has indicated that recent publications refer to patients surviving for many years after radiotherapy. In the Middlesex Hospital series (Jelliffe & Thomson 1955) there were some patients who at that time had survived for twenty years. The word 'cure' was not used in this original publication in 1955 because in those days Hodgkin's disease was still regarded as incurable and it was considered bad form to use this word when referring to it. However, follow up of this Middlesex Hospital group of patients five years later indicated that of 298 cases in which the disease was limited to lymph node involvement either above or below the diaphragm and no systemic manifestations were present, 38 % survived for ten years or longer. This group of patients was totally unselected and this suggested that cure was possible even though the treatment given to most patients was, by modern standards, totally inadequate. Obviously none of them was investigated by any of the more modem techniques. Assessment of the extent of the disease was made largely on clinical examination and a simple chest X-ray (Jelliffe 1965 ).
The emotionally highly-charged phrase 'the cure of Hodgkin's disease' was used for the first time by Easson & Russell (1963) . Their definition of cure cannot be bettered and is nowadays accepted by most clinicians. There is no doubt whatsoever that Hodgkin's disease can be cured and the cure rate is better than with many other forms of cancer.
Is Radical Investigation Justifiable ?
Because Hodgkin's disease is potentially curable, the answer to this question must be 'yes'. During the last decade, lymphography has become universally acceptable as a reasonable and useful method of demonstrating abdominal lymph node involvement. When it was first introduced, many authoritative opinions forecast innumerable unpleasant delayed complications which might even terminate fatally. As time has passed it has become clear that these gloomy prognostications were entirely unjustified and repeated lymphograms have not been followed by unexpected late complications. In our experience a few patients have had as many as three lymphograms over several years and have had no serious side-effects. The acute complications of lymphography when the patient is not carefully selected are of course now well recognized and it is not suggested that a lymphogram should be carried out without careful consideration in every patient. Other energetic investigations introduced recently have included the inferior venacavagram. Unfortunate results were also forecast for this investigation; we have seen none.
Our newest aggressive investigation is the exploratory laparotomy with splenectomy, liver biopsy and biopsy of accessible lymph nodes. Mr Marston (see above, p 111 ) has indicated that this procedure has altered our views on the extent of the disease in nearly half of our patients at the Middlesex Hospital. This probable benefit must, of course, be balanced against possible risks. It appears reasonable that knowledge of the true 50 extent of any cancer will make the management of that patient more logical, and cure more possible. But until more factual information is available as to its true benefits, limitations and risks, it is preferable to consider the procedure as experimental. It should be carried out only by experienced surgeons and its results must be carefully collected and analysed in detail.
Is Radical Treatment Justifiable?
Radical investigation is justified only because Hodgkin's disease can be cured. It is therefore obvious that radical treatment is justifiable. There are now several efficient methods of attempting to cure the disease and the main problem is the selection of the best method.
Radical Radiotherapy
The cure of cancer by irradiation is based on the assumption that all obviously neoplastic tissue must be treated. Recent concepts suggest that the human body can destroy very small tumour deposits, and in the fit human such a defence mechanism probably operates constantly, controlling the spread of microscopical deposits, and limiting the development of cancers throughout the body. With Hodgkin's disease, one unsolved problem is how much of the patient should receive irradiation in a particular case. In the past many patients have been cured by local small-field irradiation. It seems likely that many more could have been cured by more energetic treatment as advocated by some workers in the United States. The extreme of this approach is the radical irradiation of all known major lymph node groups. In order to determine which patients are best treated by these very different approaches, we have organized a collaborative group working in a number of major centres. Patients with relatively limited disease are receiving either local or wide-field radiotherapy. When lymph node involvement is generalized both above and below the diaphragm, one possible method of curing the patient is by irradiating all the major lymph node groups in the body. This we are doing, but in order to discover which patients are worth treating in this radical fashion, we are comparing this method with radical chemotherapy.
Radical Chemotherapy
Exponents of combination chemotherapy claim excellent results and the immediate response to such treatment is often dramatic. However, the long-term results are more important. A randomized comparison ofradical chemotherapy and radical radiotherapy in Stage III Hodgkin's disease is therefore essential and has been undertaken by our group. Our combination regime closely resembles that used by Carbone and De Vita in the United States and consists of vin-cristine, nitrogen mustard, procarbazone and prednisone.
It is too early to produce statistically significant figures but trends are already appearing. Certainly when the patient has no generalized systemic manifestations there is so far no difference between the results of treatment by radical chemotherapy and by radical radiotherapy.
In Stage IV Hodgkin's disease, when infiltration of tissues other than lymph nodes has occurred, the logical treatment is radical chemotherapy using a combination technique identical with that used in Stage III disease. We do not yet know how radical one must be with this approach, or how long courses of treatment should be continued. At present we are comparing a group of patients undergoing six courses of treatment followed by a period of observation, provided the patient is in complete remission, and a second group receiving six courses of treatment followed by maintenance therapy.
We do not yet know how many agents are essential to obtain the best results. Another comparison that our group is carrying out at present is between the standard quadruple regime indicated above, and a combination of drugs identical except for the omission of prednisone. So far we have noticed no difference in the two groups and it may be that corticosteroids are quite unnecessary in the initial stages of radical chemotherapy. Dr Wiltshaw and Dr Millett (see above, p 1110) have indicated that cytotoxic drug combinations can be highly effective in combating Hodgkin's disease, but it must be emphasized that treatment of this type must not be used by the casual chemotherapist. These drugs are extremely powerful and have great potential for good or evil. Just as with radical radiotherapy, long experience in a treatment technique and extensive knowledge of the natural history of the disease undergoing treatment are essential if good results are to be obtained.
Immunotherapy
Immunotherapy seems to offer serious possibility for the future, but at present we must not be put off by the known immunosuppressive effects of all our present active methods of treatment and it is better to ignore theoretical disadvantages rather than fail to benefit from the known advantages of these methods. We hope soon to be able to predict the best method for patients suffering from this uncommon disease by the continued cooperation between centres throughout the country and the accumulation of accurately recorded data. Close enthusiastic cooperation between centres is essential because onlyjust over 2000 cases are seen annually in Britain. For this reason we formed the Cooperative Clinical Cancertherapy Group, in which the National Lymphoma Investigation is being carried out. Colleagues in seventeen major centres are collaborating, and since February 1970 more than 360 patients have been referred.
AlliedLymph Node Disorders
We intend to carry out a similar controlled investigation into the treatment of other lymphomas. Obviously preliminary investigations into the factors affecting the prognosis, and trials of possible treatment methods, are essential, and we have had these under way for three years. A retrospective investigation of a large number of patients with lymphosarcoma has shown up a previously undescribed group with well-marked fibrous banding throughout the lymph nodes which carries a particularly good prognosis (Bennett & Millett 1969) . Clearly, allowance must be made for this group of low grade tumours in our forthcoming investigation. Newer treatment methods have been thoroughly examined and we are now in a position to start.
Conclusions
Hodgkin's disease is certainly not incurable, and radical investigation therefore appears fully justifiable. Radical treatment is indicated when cure is the aim. Our main problem at present is the correct choice of radical treatment and this can be solved by a careful randomized investigation carried out by large collaborating groups.
Other lymphomas may prove to be more serious problems than Hodgkin's disease but there is no justification for adopting an attitude of torpid pessimism towards these patients. Energetic investigation followed by vigorous treatment may prove successful in many cases. As with Hodgkin's disease, the true facts will emerge only after completion of an adequate randomized trial.
